Inetetamab-base regimens for patients with HER2-positive metastatic breast cancer and brain metastases: a real-world retrospective study 含伊尼妥单抗的治疗方案用于治疗HER2阳性转移性乳腺癌（包括脑转移）患者的真实世界回顾性研究 研究背景 尽管在治疗HER2阳性乳腺癌方面取得了巨大进展，但HER2阳性转移性乳腺癌（...
for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023 Feb 1;9(2):197-205.
for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2023 Feb 1;9(2):197-205.
[3]Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial...
[1]Keith KC, Lee Y, Ewend MG, et al. Activity of trastuzumab- emtansin (T-DM1) in HER2- positive breast cancer brain metastases: a case series. Cancer Treat Commun,2016, 7: 43-46. [2]Stemmler H,Schmitt MA,Bernhard H,et al.Ratio of trastuzumab levels in serum and cerebrospinal fl...
[3] Huo X, Shen G, Wang T, et al. Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis. Front Oncol. 2023;13:1003565. [4] Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer ...
[2] Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review. Cancer Treat Rev. 2023 Apr;115:102527. [3] Treatment strategies for breast cancer brain metastases. British Jou...
[14] Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38(23):2610–9. ...
3、Niikura,N.et al.Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease(ROSET-BM).NPJ Breast Cancer 9,82(2023). 4、Bartsch,R.et al.Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases:a sing...
Breast cancer brain metastasesHER2 3+ breast cancerLocally advanced HER2 3+ breast cancerdoi:182Z.I. TomasevicInstitute for Oncology and Radiology of SerbiaZ.M. TomasevicInstitute for Oncology and Radiology of SerbiaZ. KovacInstitute for Oncology and Radiology of SerbiaGlobal Journal of Breast Cancer...